Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 93

Results For "Non"

1415 News Found

Football sized rare mesenteric tumour removed laparoscopically at the CK Birla Hospital
News | September 07, 2022

Football sized rare mesenteric tumour removed laparoscopically at the CK Birla Hospital

In a rare occurrence worldwide, the CK Birla Hospital® treats 32-year-old woman for a giant mesenteric tumour via complex laparoscopic surgery


AstraZeneca partners with Alveofit to scale up the diagnosis and treatment of lung diseases in India
News | September 05, 2022

AstraZeneca partners with Alveofit to scale up the diagnosis and treatment of lung diseases in India

This partnership aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.


Medix Biochemica appoints former Roche executive to its Board of Directors
People | September 01, 2022

Medix Biochemica appoints former Roche executive to its Board of Directors

Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.


Bayer showcases cancer study data at ESMO Congress 2022
News | September 01, 2022

Bayer showcases cancer study data at ESMO Congress 2022

On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors


A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert
Healthcare | September 01, 2022

A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert

India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved


Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian
Clinical Trials | September 01, 2022

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke


Hydration of proteins could act as a potential marker for an early detection of neuro-degenerative diseases
News | September 01, 2022

Hydration of proteins could act as a potential marker for an early detection of neuro-degenerative diseases

This dense phase often resembles liquid droplets exhibiting higher protein density and weaker molecular motion than the surrounding medium.


Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA
Clinical Trials | September 01, 2022

Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA

COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan


Merck to present new data of oncology portfolio at ESMO 2022
Clinical Trials | August 30, 2022

Merck to present new data of oncology portfolio at ESMO 2022

Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)